Onkológia 5/2016

Monoclonal antibodies in treatment of multiple myeloma

Despite the advances in treatment, multiple myeloma (MM) remains mostly incurable disease and patients refractory to therapy survival in average less than a year. The proteasome inhibitors and immunomodulatory drugs significantly improved survival, but new therapeutic challenge can be met to believe that multipme myeloma is a fundamentally curable disease. This has driven the development of new therapies including not only next-generation proteasome inhibitors, but including also histone deacetylase inhibitors and a number of MoAb function as anticancer agents. In the past decade, technological advancements and an evolving understanding of the pathophysiology of complex and heterogeneous nature of MM have permitted the identification of target antigens and the development of a number of novel MoAb that are demonstranting clinically meaningful efficacy. In this review, we evaluate the promise of targeted therapy for MM in light of the key clinical data, focusing on the exciting recent developments in MoAb- based therapy for this disease. Methods: We selectively searched the PubMed database for pertinent articles and guidelines from the years 2005-2016. We used the search term „multiple myeloma and monoclonal antibodies“.

Keywords: multiple myeloma, monoclonal antibodies